76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
L Lisata Therapeutics
L
Closed
2.41 -0.41
Overview
Share price change
24h
Min
2.41
Max
2.51
Employees | 26 |
|---|
Recommendations | Buy |
|---|---|
12 Months Forecast | +875.1% upside |
Next Earnings | 11 Aug 2025 |
|---|
Market Cap | -934K 19M |
|---|---|
Previous open | 2.82 |
Previous close | 2.41 |
Lisata Therapeutics Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Lisata Therapeutics Forecast
Price Target
By TipRanks
875.1% upside
12 Months Forecast
Average 23.5 USD 875.1%
High 32 USD
Low 15 USD
Based on 2 Wall Street analysts offering 12 month price targets forLisata Therapeutics - Dist in the last 3 months.
Financials
$
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
